Do analysts recommend PRPH or TRIB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Trinity Biotech 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts rate QLGN or PRPH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer ORGS or PRPH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ORGS or PRPH more profitable?

ProPhase Labs has a net margin of -825.01% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat ProPhase Labs' return on equity. Company Net Margins Return on Equity Return on Assets Orgenesis -3,827.81% N/A -130.18% ProPhase Labs -825.01% -482.05% -88.90%

Does the media refer more to ORGS or PRPH?

In the previous week, Orgenesis and Orgenesis both had 1 articles in the media. Orgenesis' average media sentiment score of 0.00 equaled ProPhase Labs'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Orgenesis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProPhase Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CANF or PRPH?

Can-Fite BioPharma currently has a consensus price target of $42.50, indicating a potential upside of 1,360.48%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Can-Fite BioPharma is more favorable than ProPhase Labs. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Can-Fite BioPharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to CANF or PRPH?

In the previous week, Can-Fite BioPharma had 1 more articles in the media than ProPhase Labs. MarketBeat recorded 2 mentions for Can-Fite BioPharma and 1 mentions for ProPhase Labs. ProPhase Labs' average media sentiment score of 0.00 beat Can-Fite BioPharma's score of -0.26 indicating that ProPhase Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Can-Fite BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProPhase Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend VAXX or PRPH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxxinity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

ProPhase Labs (PRPH) Competitors

$0.10 0.00 (0.00%)

As of 06/9/2026 01:30 PM Eastern

Compare

PRPH vs. TRIB, QLGN, ORGS, CANF, and VAXX

Should you buy ProPhase Labs stock or one of its competitors? MarketBeat compares ProPhase Labs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ProPhase Labs include Trinity Biotech (TRIB), Qualigen Therapeutics (QLGN), Orgenesis (ORGS), Can-Fite BioPharma (CANF), and Vaxxinity (VAXX). These companies are all part of the "pharmaceutical products" industry.

How does ProPhase Labs compare to Trinity Biotech?

ProPhase Labs (NASDAQ:PRPH) and Trinity Biotech (NASDAQ:TRIB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

In the previous week, ProPhase Labs and ProPhase Labs both had 1 articles in the media. Trinity Biotech's average media sentiment score of 1.78 beat ProPhase Labs' score of 0.00 indicating that Trinity Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
ProPhase Labs	Neutral
Trinity Biotech	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Trinity Biotech	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Trinity Biotech has a net margin of -85.36% compared to ProPhase Labs' net margin of -825.01%. Trinity Biotech's return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
Trinity Biotech	-85.36%	N/A	-36.61%

Trinity Biotech has higher revenue and earnings than ProPhase Labs. Trinity Biotech is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.06M	0.12	-$53.36M	-$3.90	N/A
Trinity Biotech	$43.78M	0.05	-$37.38M	-$3.90	N/A

9.4% of ProPhase Labs shares are held by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are held by institutional investors. 9.6% of ProPhase Labs shares are held by insiders. Comparatively, 8.2% of Trinity Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Trinity Biotech beats ProPhase Labs on 8 of the 11 factors compared between the two stocks.

How does ProPhase Labs compare to Qualigen Therapeutics?

Qualigen Therapeutics (NASDAQ:QLGN) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

In the previous week, ProPhase Labs had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 1 mentions for ProPhase Labs and 0 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.00 equaled ProPhase Labs'average media sentiment score.

Company	Overall Sentiment
Qualigen Therapeutics	Neutral
ProPhase Labs	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Qualigen Therapeutics has higher earnings, but lower revenue than ProPhase Labs. Qualigen Therapeutics is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A
ProPhase Labs	$5.06M	0.12	-$53.36M	-$3.90	N/A

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are owned by institutional investors. 1.8% of Qualigen Therapeutics shares are owned by insiders. Comparatively, 9.6% of ProPhase Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Qualigen Therapeutics has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Qualigen Therapeutics' return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	N/A	-202.16%
ProPhase Labs	-825.01%	-482.05%	-88.90%

Qualigen Therapeutics has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market.

Summary

ProPhase Labs beats Qualigen Therapeutics on 7 of the 11 factors compared between the two stocks.

How does ProPhase Labs compare to Orgenesis?

Orgenesis (NASDAQ:ORGS) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ProPhase Labs has higher revenue and earnings than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662K	3.12	-$55.36M	-$11.51	N/A
ProPhase Labs	$5.06M	0.12	-$53.36M	-$3.90	N/A

In the previous week, Orgenesis and Orgenesis both had 1 articles in the media. Orgenesis' average media sentiment score of 0.00 equaled ProPhase Labs'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Orgenesis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProPhase Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Orgenesis has a beta of 2.89, meaning that its stock price is 189% more volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market.

ProPhase Labs has a net margin of -825.01% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
ProPhase Labs	-825.01%	-482.05%	-88.90%

22.6% of Orgenesis shares are held by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are held by institutional investors. 1.9% of Orgenesis shares are held by company insiders. Comparatively, 9.6% of ProPhase Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

ProPhase Labs beats Orgenesis on 8 of the 12 factors compared between the two stocks.

How does ProPhase Labs compare to Can-Fite BioPharma?

Can-Fite BioPharma (NYSE:CANF) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Can-Fite BioPharma has higher earnings, but lower revenue than ProPhase Labs. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Can-Fite BioPharma	$405K	4.71	-$7.63M	-$35.80	N/A
ProPhase Labs	$5.06M	0.12	-$53.36M	-$3.90	N/A

Can-Fite BioPharma has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market.

Can-Fite BioPharma has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Can-Fite BioPharma's return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
ProPhase Labs	-825.01%	-482.05%	-88.90%

Can-Fite BioPharma currently has a consensus price target of $42.50, indicating a potential upside of 1,360.48%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Can-Fite BioPharma is more favorable than ProPhase Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Can-Fite BioPharma had 1 more articles in the media than ProPhase Labs. MarketBeat recorded 2 mentions for Can-Fite BioPharma and 1 mentions for ProPhase Labs. ProPhase Labs' average media sentiment score of 0.00 beat Can-Fite BioPharma's score of -0.26 indicating that ProPhase Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Can-Fite BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProPhase Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

21.0% of Can-Fite BioPharma shares are held by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by insiders. Comparatively, 9.6% of ProPhase Labs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Can-Fite BioPharma beats ProPhase Labs on 11 of the 16 factors compared between the two stocks.

How does ProPhase Labs compare to Vaxxinity?

Vaxxinity (NASDAQ:VAXX) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxxinity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Vaxxinity has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Vaxxinity's return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxxinity	N/A	N/A	N/A
ProPhase Labs	-825.01%	-482.05%	-88.90%

82.9% of Vaxxinity shares are owned by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are owned by institutional investors. 64.1% of Vaxxinity shares are owned by insiders. Comparatively, 9.6% of ProPhase Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, ProPhase Labs had 1 more articles in the media than Vaxxinity. MarketBeat recorded 1 mentions for ProPhase Labs and 0 mentions for Vaxxinity. Vaxxinity's average media sentiment score of 0.00 equaled ProPhase Labs'average media sentiment score.

Company	Overall Sentiment
Vaxxinity	Neutral
ProPhase Labs	Neutral

Vaxxinity has a beta of -79.33, suggesting that its stock price is 8,033% less volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

ProPhase Labs has higher revenue and earnings than Vaxxinity. Vaxxinity is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxxinity	N/A	N/A	-$56.93M	-$0.45	N/A
ProPhase Labs	$5.06M	0.12	-$53.36M	-$3.90	N/A

Summary

Vaxxinity and ProPhase Labs tied by winning 6 of the 12 factors compared between the two stocks.

Get ProPhase Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRPH vs. The Competition

Export

Metric	ProPhase Labs	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$602K	$2.96B	$6.65B	$12.06B
Dividend Yield	N/A	1.71%	2.67%	5.55%
P/E Ratio	-0.03	17.78	24.50	23.76
Price / Sales	0.12	287.11	506.39	105.22
Price / Cash	N/A	55.74	42.36	56.09
Price / Book	0.04	3.88	10.30	6.72
Net Income	-$53.36M	$75.85M	$3.56B	$337.35M
7 Day Performance	N/A	-1.11%	-0.98%	-1.21%
1 Month Performance	N/A	-5.33%	1.23%	1.41%
1 Year Performance	N/A	13.23%	20.44%	23.64%

ProPhase Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRPH ProPhase Labs	0.0843 of 5 stars	$0.10 flat	N/A	-97.2%	$602K	$5.06M	N/A	130
TRIB Trinity Biotech	0.8873 of 5 stars	$0.66 -2.3%	N/A	-79.7%	$2.39M	$43.79M	N/A	480	Positive News
QLGN Qualigen Therapeutics	N/A	$1.29 +11.2%	N/A	-64.7%	$2.19M	N/A	N/A	50	Gap Up
ORGS Orgenesis	N/A	$0.40 -19.2%	N/A	-82.4%	$2.07M	$662K	N/A	150	Gap Down
CANF Can-Fite BioPharma	2.1019 of 5 stars	$2.91 -5.5%	$42.50 +1,360.5%	-86.9%	$1.91M	$405K	N/A	8

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRPH) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProPhase Labs (PRPH) Competitors

PRPH vs. TRIB, QLGN, ORGS, CANF, and VAXX

How does ProPhase Labs compare to Trinity Biotech?

Summary

How does ProPhase Labs compare to Qualigen Therapeutics?

Summary

How does ProPhase Labs compare to Orgenesis?

Summary

How does ProPhase Labs compare to Can-Fite BioPharma?

Summary

How does ProPhase Labs compare to Vaxxinity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRPH vs. The Competition

ProPhase Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ProPhase Labs (PRPH) Competitors

PRPH vs. TRIB, QLGN, ORGS, CANF, and VAXX

How does ProPhase Labs compare to Trinity Biotech?

Does the media refer more to PRPH or TRIB?

Do analysts recommend PRPH or TRIB?

Is PRPH or TRIB more profitable?

Which has preferable valuation and earnings, PRPH or TRIB?

Do institutionals and insiders hold more shares of PRPH or TRIB?

Summary

How does ProPhase Labs compare to Qualigen Therapeutics?

Does the media prefer QLGN or PRPH?

Do analysts rate QLGN or PRPH?

Which has preferable earnings & valuation, QLGN or PRPH?

Do insiders and institutionals believe in QLGN or PRPH?

Is QLGN or PRPH more profitable?

Which has more volatility and risk, QLGN or PRPH?

Summary

How does ProPhase Labs compare to Orgenesis?

Do analysts prefer ORGS or PRPH?

Which has better valuation and earnings, ORGS or PRPH?

Does the media refer more to ORGS or PRPH?

Which has more volatility and risk, ORGS or PRPH?

Is ORGS or PRPH more profitable?

Do insiders & institutionals believe in ORGS or PRPH?

Summary

How does ProPhase Labs compare to Can-Fite BioPharma?

Which has higher earnings & valuation, CANF or PRPH?

Which has more risk & volatility, CANF or PRPH?

Is CANF or PRPH more profitable?

Do analysts prefer CANF or PRPH?

Does the media refer more to CANF or PRPH?

Do institutionals and insiders believe in CANF or PRPH?

Summary

How does ProPhase Labs compare to Vaxxinity?

Do analysts recommend VAXX or PRPH?

Is VAXX or PRPH more profitable?

Do institutionals & insiders have more ownership in VAXX or PRPH?

Does the media prefer VAXX or PRPH?

Which has more volatility and risk, VAXX or PRPH?

Which has stronger earnings & valuation, VAXX or PRPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRPH vs. The Competition

ProPhase Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools